Autotaxin as Abiomarker in Systemic Lupus Erythematosus Patients
NCT06063668 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 94
Last updated 2023-10-03
Summary
* Estimation of the serum ATX level in SLE patients in comparison to healthy subjects.
* Evaluation of the relation of serum ATX level with disease activity and different clinical manifestation in SLE patients
Conditions
- SLE (Systemic Lupus)
Sponsors & Collaborators
-
Assiut University
lead OTHER
Principal Investigators
-
Nada Mohamed Gamal Abd-Elaleem, Ass. Prof · Assiut University
-
Maha Sayed Ibrahim Abdelrahman, Lecturer · Assiut University
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-10-31
- Primary Completion
- 2024-10-31
- Completion
- 2025-10-31
More Related Trials
-
Assessment of Blood Indices in Systemic Lupus Erythematosus
NCT06872086 ·Status: NOT_YET_RECRUITING
-
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity
NCT06610409 ·Status: NOT_YET_RECRUITING
-
Chemokine (CXCL13) as Anew Marker in Diagnosis of SLE
NCT03752983 ·Status: UNKNOWN
-
Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus.
NCT06294483 ·Status: ENROLLING_BY_INVITATION
-
Autophagy in Systemic Lupus Erythematosus
NCT03583853 ·Status: UNKNOWN
-
Anemia in Systemic Lupus Erythematosus Specially Refractory Type
NCT06210295 ·Status: NOT_YET_RECRUITING
-
Clinical and Diagnostic Value of Ribosomal p2 Autoantibodies in Systemic Lupus Erythematosus
NCT05179018 ·Status: UNKNOWN
-
Anti-ficolin-2 Autoantibodies in Lupus Nephritis
NCT03063281 ·Status: COMPLETED
-
Clinical Characteristics and Outcomes of SLE Patients Admitted to Critical Care Unit
NCT05418855 ·Status: UNKNOWN
-
Anti KU Antibodies and Its Relationship With Systemic Lupus Erythematosus
NCT05900232 ·Status: UNKNOWN ·Phase: NA
-
The Relation of Albumin/Globulin Ratio and Platelet/Albumin Ratio to Lupus Nephritis
NCT07130448 ·Status: NOT_YET_RECRUITING
-
Serum IL 26 as a Marker of Disease Activity in SLE
NCT05161988 ·Status: UNKNOWN
-
Anti-ficolin-3 Autoantibodies in Lupus Nephritis
NCT02625831 ·Status: COMPLETED
-
Evaluation of Serum Galectin-9 Level in Systemic Lupus Erythematosus Patients and it's Association With Disease Activity and Organ Damage
NCT04558814 ·Status: UNKNOWN ·Phase: NA
-
Relation of Antibodies Against Oxidized Low Density Lipoproteins to Disease Activity and Cardiovascular Affection in Systemic Lupus.
NCT05479071 ·Status: UNKNOWN
-
SSerum/Urinary Monocyte Chemoattractant Protein-1 Level as a Marker for Lupus Nephritis
NCT03164720 ·Status: UNKNOWN
-
Systemic Immune Inflammatory Index in Systemic Lupus Erythematosus
NCT06796569 ·Status: RECRUITING
-
Renal Arterial Resistive Index as a Noninvasive Biomarker of Disease Activity in Lupus Nephritis Patients
NCT06631404 ·Status: RECRUITING
-
This Project Aims to Understand the Needs of Rheumatologists and Other Specialties in the Care of Patients With SLE
NCT06698900 ·Status: COMPLETED
-
Glycosylation Analysis of Lupus Anti-DNA Antibodies (GALA)
NCT05394922 ·Status: RECRUITING
-
Hematological Manifestations in Systemic Lupus Erythematosus Patients
NCT06936007 ·Status: COMPLETED
-
The Efficacy and Safety of Telitacicept and Belimumab in Active Lupus Nephritis in the Real World: a Prospective Cohort Study
NCT05588830 ·Status: UNKNOWN
-
Cardiac and Laboratory Findings in Patients With Systemic Lupus Erythematosus
NCT03179046 ·Status: COMPLETED
-
Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
NCT01702038 ·Status: WITHDRAWN ·Phase: PHASE2
-
Fatigue, Depression, and Cortical Excitability in Systemic Lupus
NCT03165682 ·Status: UNKNOWN